2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Carcinoma, Renal Cell
5
Neoplasms
4
Carcinoma, Hepatocellular
4
Lung Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
3
Ovarian Neoplasms
2
Neoplasm, Residual
2
NSCLC
2
Kidney Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Philadelphia Chromosome
1
Neoplasms, Second Primary
1
Neoplasms by Site
1
Lung Diseases
1
Liver Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cytarabine
86
fludarabine phosphate
85
Peripheral Blood Stem Cell Transplantation
76
Cyclophosphamide
69
Busulfan
63
Mycophenolic Acid
51
Tacrolimus
48
Cyclosporine
48
Etoposide
43
Whole-Body Irradiation
42
Antilymphocyte Serum
40
Methotrexate
39
Filgrastim
39
Flow Cytometry
30
Radiotherapy
29
Melphalan
24
Mitoxantrone
23
Daunorubicin
23
Idarubicin
21
Cord Blood Stem Cell Transplantation
19
Polymerase Chain Reaction
17
Methylprednisolone
17
Gene Expression Profiling
17
sargramostim
15
Granulocyte Colony-Stimulating Factor
15
Clofarabine
15
Transplantation
14
Decitabine
14
Gemtuzumab
13
aldesleukin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Abnormalities
×
Tyrosine Kinase Inhibitors
×
Clear all
NCT04151342
2025-12-03
CARMA-BROS
University Health Network, Toronto
Recruiting
5,500 enrolled